Incyte | INCY - Trade Debtors


Incyte reported $1.13B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agenus USD 22.34M 107K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Exelixis USD 322.21M 6.73M Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Merck USD 12.21B 435M Mar/2026
Moderna USD 17M 54M Jun/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.85B 252M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.19B 19M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026